Evidence map›Paper›PMID 42029637›Full record

ReviewEpigenomes2026

Natural Compounds as Epimodulators in Epithelial Ovarian Cancer.

Mélida Del Rosario Lizarazo-Taborda, Julio César Villegas-Pineda, Holver Parada, Fabian Galvis, Javier Soto

Abstract readReview
In one paragraph

Review in Epigenomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mélida Del Rosario Lizarazo-TabordaLaboratorio de Investigación en Cáncer e Infecciones (LICI), Departamento de Microbiología y Patología, CUCS, UDG, Guadalajara 44340, Jalisco, Mexico.
Julio César Villegas-PinedaLaboratorio de Investigación en Cáncer e Infecciones (LICI), Departamento de Microbiología y Patología, CUCS, UDG, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-0015-9444
Holver ParadaFacultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, Universidad de Santander, Cúcuta 540003, Norte de Santander, Colombia.ORCID 0000-0002-2308-656X
Fabian GalvisGrupo de Investigación Majumba, Facultad de Ciencias Básicas, Universidad Francisco de Paula Santander, Cúcuta 540003, Norte de Santander, Colombia.
Javier SotoFacultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, Universidad de Santander, Cúcuta 540003, Norte de Santander, Colombia.ORCID 0000-0002-4786-3431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian carcinoma (EOC) is the most common type of ovarian cancer and represents the most lethal gynecologic neoplasm. EOC is usually diagnosed at late stages due to its nonspecific signs and symptoms. Although significant clinical advances have been made in other types of malignancies, EOC remains a disease that requires further biological research to identify new therapeutic targets or new treatment alternatives, as conventional approaches are often ineffective or lead to the development of resistance and unwanted side effects. There are a significant number of natural products from which commercially available drugs have been derived, largely for the treatment of cancer, but none of them focus on epigenetic changes in specific targets in EOC. Based on the above, this work focuses on describing the in vitro and in vivo findings from the last twelve years derived from the action of important phytochemicals on epigenetic targets in ovarian cancer, among other mechanisms of action, revealing that there is a significant gap to be bridged in terms of the transition from basic to applied research regarding the potential of plant-derived molecules as possible epidrugs in EOC.

Indexed as

epigenetic changesepithelial ovarian cancerphytochemicals

Identifiers

PMID42029637
PMCPMC13108203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.